Gubra A/S - Asset Resilience Ratio
Gubra A/S (GUBRA) has an Asset Resilience Ratio of 56.76% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Gubra A/S balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how Gubra A/S's Asset Resilience Ratio has changed over time. See Gubra A/S (GUBRA) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Gubra A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Gubra A/S market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr1.65 Billion | 56.76% |
| Total Liquid Assets | Dkr1.65 Billion | 56.76% |
Asset Resilience Insights
- Very High Liquidity: Gubra A/S maintains exceptional liquid asset reserves at 56.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Gubra A/S Industry Peers by Asset Resilience Ratio
Compare Gubra A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 20.53% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 65.08% |
|
AbClon Inc
KQ:174900 |
Biotechnology | 14.74% |
|
Opthea Ltd
AU:OPT |
Biotechnology | 60.86% |
Annual Asset Resilience Ratio for Gubra A/S (2023–2024)
The table below shows the annual Asset Resilience Ratio data for Gubra A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 47.00% | Dkr287.84 Million ≈ $45.03 Million |
Dkr612.48 Million ≈ $95.83 Million |
-17.61pp |
| 2023-12-31 | 64.61% | Dkr403.99 Million ≈ $63.21 Million |
Dkr625.28 Million ≈ $97.83 Million |
-- |
About Gubra A/S
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metab… Read more